AMRI Opens New Research Facility in Budapest, Hungary

Laboratory Expansion Strengthens Commitment to Chemistry R&D Platform in Europe

24-Jun-2009 - AMRI announced that it has finished the construction of a new state-of-the-art chemistry R&D facility in Budapest, Hungary. The successful completion and move into 32,300 square feet (3,000 square meters) of laboratory and administrative space marks a significant milestone in the company’s plan ...

AMRI Names Senior Director, Analytical and Quality Services

14-Jan-2009 - AMRI announced that Junan Guo, Ph.D. has joined the company as senior director, analytical and quality services. Dr. Guo fills the role vacated by Dr. Steven Hagen, who was promoted to vice president of pharmaceutical development and manufacturing in September 2008. Dr. Guo will oversee all ...

AMRI Names New Chemistry Director at Its European Site

30-Nov-2007 - AMRI has named Dr. Philip William Small as director of chemistry at its Hungarian site. In his new position, Dr. Small will assume responsibilities for all of AMRI's European chemistry related activities including custom synthesis, medicinal chemistry, analytical services, library design and ...

Albany Molecular Research, Inc. Renews Relationship with Eli Lilly and Company

11-Feb-2005 - Albany Molecular Research, Inc. announced a new drug discovery research agreement with Eli Lilly and Company, continuing an ongoing relationship between the two companies that began in 1998. Under the terms of the agreement, AMRI will provide fee-for-service chemistry research on projects in ...

Albany Molecular Research, Inc. Establishes Singapore Research Centre

19-Jan-2005 - Albany Molecular Research, Inc. announced that it has established a wholly owned subsidiary, Albany Molecular Research Singapore Research Centre, Pte Ltd (AMRSRC). AMRI expects to initiate operations in Singapore in the first quarter of 2005, with the goal of providing a full range of ...

Albany Molecular Research, Inc. Announces Restructuring of Research Departments

22-Mar-2004 - Albany Molecular Research, Inc. announced a restructuring of several research departments and corresponding senior management promotions. Michael P. Trova, Ph.D. has been named to the newly created position of senior vice president, chemistry. In his new role, Dr. Trova assumes responsibility ...

AMRI Announces Natural Products Research Collaboration with Eli Lilly and Company

13-Feb-2003 - Albany Molecular Research, Inc. (Nasdaq: AMRI) has entered into a three-year natural products research collaboration focused on screening and lead identification with Eli Lilly and Company (Lilly). The goal of the collaboration is to discover and develop potential therapeutic agents for ...

Albany Molecular Research, Inc. Opens New Analytical Labs

19-Nov-2002 - Albany Molecular Research, Inc.opened two new state-of-the-art analytical chemistry laboratories at a ribbon-cutting ceremony with AMRI Chairman and CEO Thomas E. D'Ambra, Ph.D. and Albany Mayor Gerald D. Jennings. Analytical scientists utilize various techniques to ensure the identity and ...

Albany Molecular Research and Nobex Announce Joint Research Program

Nobex to Gain Ready Access to Chemistry for Improving Drug Delivery

05-Mar-2002 - Albany, NY and Research Triangle Park, North Carolina, March 4, 2002 - Nobex Corporation and Albany Molecular Research, Inc. (Nasdaq: AMRI) announced today that they have entered into a collaborative research program to develop a comprehensive library of Nobex proprietary polymers for use in ...

Albany Molecular Research, Inc. Announces New Relationship with Bristol-Myers Squibb Company

20-Feb-2002 - Albany, NY (February 19, 2002) - Albany Molecular Research, Inc. today announced it has signed a letter-of-intent with Bristol-Myers Squibb Company to replace its contract with the former DuPont Pharmaceuticals Company, which was acquired by Bristol-Myers Squibb in October 2001. Negotiations on a ...